top of page
Active, not recruiting

NCT02465060: Phase 2: Targeted Therapy Directed by Genetic Testing in Treating Patients With RRMM

Updated: Feb 10

  • NCT02465060: phase 2: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)


match

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)


This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.


Sponsor


 

ClinicalTrials.gov Identifier: NCT02465060

Official Title: Molecular Analysis for Therapy Choice (MATCH)

First Posted: June 8, 2015

Click here for details on ClinicalTrials.gov


 

Drug: Adavosertib

Drug: Afatinib

Drug: Afatinib Dimaleate

Drug: Binimetinib

Drug: Capivasertib

Drug: Copanlisib

Drug: Copanlisib Hydrochloride

Drug: Crizotinib

Other: Cytology Specimen Collection Procedure

Drug: Dabrafenib

Drug: Dabrafenib Mesylate

Drug: Dasatinib

Drug: Defactinib

Drug: Defactinib Hydrochloride

Drug: Erdafitinib

Drug: FGFR Inhibitor AZD4547

Drug: Ipatasertib

Other: Laboratory Biomarker Analysis

Drug: Larotrectinib

Drug: Larotrectinib Sulfate

Biological: Nivolumab

Drug: Osimertinib

Drug: Palbociclib

Biological: Pertuzumab

Drug: PI3K-beta Inhibitor GSK2636771

Biological: Relatlimab

Drug: Sapanisertib

Drug: Sunitinib Malate

Drug: Taselisib

Drug: Trametinib

Biological: Trastuzumab

Biological: Trastuzumab Emtansine

Drug: Ulixertinib

Drug: Vismodegib

 

Locations

United States, Alabama

United States, Alaska

United States, Arizona

United States, Arkansas

United States, California

United States, Colorado

United States, Connecticut

United States, Delaware

United States, District of Columbia

United States, Florida

United States, Georgia

United States, Hawaii

United States, Idaho

United States, Illinois

United States, Indiana

United States, Iowa

United States, Kansas

United States, Kentucky

United States, Louisiana

United States, Maine

United States, Maryland

United States, Massachusetts

United States, Michigan

United States, Minnesota

United States, Mississippi

United States, Missouri

United States, Montana

United States, Nebraska

United States, Nevada

United States, New Jersey

United States, New Mexico

United States, New York

United States, North Carolina

United States, North Dakota

United States, Ohio

United States, Oklahoma

United States, Oregon

United States, Pennsylvania

United States, Rhode Island

United States, South Carolina

United States, South Dakota

United States, Tennessee

United States, Texas

United States, Utah

United States, Vermont

United States, Virginia

United States, Washington

United States, West Virginia

United States, Wisconsin

United States, Wyoming

Guam

Puerto Rico

 

Other ECOG Trials



NCT04566328: Phase 3 - EAA181 / EQUATE - Testing the Use of Combination Therapy in NDMM


NCT03937635: Phase 3 - EAA173 / DETER-SMM - Lenalidomide, Dex +/- Daratumumab in High-Risk Smoldering Myeloma


NCT03941860: Phase 3 - EAA171 / OPTIMUM - Addition of Ixazomib to Lenalidomide in Patients With Residual Myeloma


NCT02465060: Phase 2 - EAY131 / NCI-MATCH - Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)







Posts Archive
bottom of page